Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$101.4B

Jul28Tue

Pre-Earnings Brief

UpcomingQ1-2011Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $101 billion, it plays a significant role in the health care sector, particularly in developing treatments for various diseases and conditions.

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$1.16

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2011 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK reported an EPS of $0.45, significantly missing the estimate of $0.88. This disappointing performance led to a stock increase of 2.79% the following day, indicating some investor optimism despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report an EPS of $1.16 and revenue of $7.6 billion. The market is watching closely for any signs of recovery from previous earnings misses.

Bull Case

If GSK can exceed the EPS estimate, it may signal a turnaround in its product performance and investor confidence could increase, driving the stock higher.

Bear Case

A miss on EPS or revenue could reinforce concerns about GSK's growth prospects and lead to further declines in the stock price.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$7.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK meet or exceed the consensus EPS estimate of $1.16?

This figure is crucial for assessing the company's recovery from past earnings misses and could significantly influence investor sentiment.

What are the management's comments on revenue growth and product pipeline?

Insights into revenue growth and the pipeline will help gauge the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GSK's potential for recovery, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

GSK's recent investments in R&D may not be fully reflected in current estimates.

Options pricing suggests a larger expected move than historical performance indicates, hinting at potential volatility.

The company's strong pipeline of new drugs could lead to better-than-expected sales.

Key Risk

If GSK's new product sales exceed expectations, it could invalidate the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether GSK can turn around its recent performance after several earnings misses.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.15 would indicate continued struggles and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±10.8%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating uncertainty among investors.

Options are pricing ±10.8% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (67K)P/C Ratio: 0.41Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline in stock price, with historical data suggesting an average drop of 0.83%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of new drug launches.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on margins.
4Insights into competitive pressures in the pharmaceutical market.
5Any changes in guidance or expectations for the full fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$1.16

Revenue

Total revenue gives insight into the company's sales performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2011 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report an EPS of $1.16 and revenue of $7.6 billion. The market is watching closely for any signs of recovery from previous earnings misses.

Bull Case

If GSK can exceed the EPS estimate, it may signal a turnaround in its product performance and investor confidence could increase, driving the stock higher.

Bear Case

A miss on EPS or revenue could reinforce concerns about GSK's growth prospects and lead to further declines in the stock price.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$7.6B

Total revenue gives insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK meet or exceed the consensus EPS estimate of $1.16?

This figure is crucial for assessing the company's recovery from past earnings misses and could significantly influence investor sentiment.

What are the management's comments on revenue growth and product pipeline?

Insights into revenue growth and the pipeline will help gauge the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GSK's potential for recovery, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

GSK's recent investments in R&D may not be fully reflected in current estimates.

Options pricing suggests a larger expected move than historical performance indicates, hinting at potential volatility.

The company's strong pipeline of new drugs could lead to better-than-expected sales.

Key Risk

If GSK's new product sales exceed expectations, it could invalidate the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether GSK can turn around its recent performance after several earnings misses.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.15 would indicate continued struggles and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±10.8%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, indicating uncertainty among investors.

Options are pricing ±10.8% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (67K)P/C Ratio: 0.41Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive shift in investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline in stock price, with historical data suggesting an average drop of 0.83%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of new drug launches.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and their impact on margins.
4Insights into competitive pressures in the pharmaceutical market.
5Any changes in guidance or expectations for the full fiscal year.